CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Standard-risk adult acute lymphoblastic leukemia (ALL) patients treated with chemotherapy have unsatisfactory outcomes.
• Current risk stratification may not adequately identify all patients who will benefit from chemotherapy alone.
• CD20 expression is a potential marker for refining prognostication in ALL.

Purpose of the Study:

• To re-evaluate the risk stratification system for adult Philadelphia-negative B cell precursor-ALL.
• To investigate the impact of CD20 expression on treatment response and survival outcomes.
• To identify patient subgroups that may require alternative therapeutic strategies.

Main Methods:

• Retrospective analysis of 217 newly diagnosed adult Philadelphia-negative B cell precursor-ALL patients.
• Evaluation of CD20 expression and classic risk factors at diagnosis.
• Survival analyses conducted on 136 patients treated with chemotherapy alone.

Main Results:

• CD20-positive ALL patients had lower rates of durable complete remission compared to CD20-negative patients (81.1% vs. 94.9%).
• Within the standard-risk group, CD20-negative patients achieved higher complete remission (100% vs. 83.3%) and durable CR1 (100% vs. 82.4%) rates.
• Three-year disease-free survival and overall survival rates were significantly lower for CD20-positive standard-risk and all high-risk groups compared to CD20-negative standard-risk patients.

Conclusions:

• CD20-negative standard-risk B cell precursor-ALL indicates a favorable prognosis.
• CD20-positive standard-risk ALL patients may benefit from alternative therapies, potentially including allogeneic stem cell transplantation.
• CD20 expression is a valuable addition to existing risk stratification for adult ALL.